Could a common asthma drug help newborns breathe easier?

NCT ID NCT05527704

Ongoing Symptom relief Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether inhaled salbutamol, a drug used for asthma, can help newborns with transient tachypnoea (rapid breathing after birth). About 608 babies born between 32 and 42 weeks will receive either salbutamol or a placebo. The goal is to see if the drug reduces the need for breathing support and prevents complications like persistent pulmonary hypertension.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: salbutamol (also known as albuterol)
What this could lead to: If it works, this could provide a safe, inhaled treatment to help newborns with rapid breathing recover faster and need less breathing support.
What could go wrong: This is a late-stage trial, but the effect may be modest or not better than placebo. Side effects like rapid heart rate or low potassium are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PPHN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory failure TTN-related myopathy persistent fetal circulation syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PPHN RESPIRATORY FAILURE TTN

Contacts and locations

Locations

Medical University of Warsaw

Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.